This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignee: Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Christian Kesenheimer: Innovator in Senescence Tracers and Halogenated Benzoxazines
Introduction
Christian Kesenheimer is a notable inventor based in Dusslingen, Germany. He has made significant contributions to the field of medical diagnostics through his innovative patents. With a total of 2 patents, Kesenheimer's work focuses on compounds that aid in the visualization of cell senescence and the diagnosis of diseases.
Latest Patents
Kesenheimer's latest patents include "Senescence Tracers," which relates to novel compounds useful for visualizing cell senescence. This invention particularly emphasizes the preparation and use of fucose and amino-quinoline derivatives as senescence tracers. Another significant patent is "Halogenated Benzoxazines and Their Use," which discusses novel halogenated benzoxazines and their production methods. This invention is particularly relevant for diagnosing diseases, including dementia and Alzheimer's disease, in both humans and animals.
Career Highlights
Christian Kesenheimer is affiliated with the Eberhard Karls University of Tübingen, specifically within the Faculty of Medicine. His academic background and research focus have positioned him as a key figure in the development of innovative medical diagnostics.
Collaborations
Kesenheimer has collaborated with notable colleagues, including Bernd J. Pichler and Jonathan Cotton. These partnerships have further enhanced his research and contributions to the field.
Conclusion
Christian Kesenheimer's work in developing senescence tracers and halogenated benzoxazines showcases his commitment to advancing medical diagnostics. His innovative patents reflect a dedication to improving the understanding and treatment of critical diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile